surmount-1 tirzepatide weight loss nondiabetic For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The SURMOUNT-1: Adults achieve weight loss
Description
Instead of jumping from 2.5 mg to 5 mg, they might go to 3.5 mg first
Tirzepatide shelf life in the fridge varies by pharmacy and formulation but is typically 30-90 days for compounded products
Its efficacy and the severity of adverse effects depend on the right dosage
Both medications share a similar side effect profile because both activate the GLP-1 receptor
Medications from pharmacies that follow FDA regulations are safer, even if they cost more
As decreasing glucose levels and alcohol-seeking behavior are 2 dual effects of GLP-1 receptor agonists, the dosage can be adjusted accordingly to achieve the desired benefits while reducing the potential side effects of the drug class
